Bob Seevers

Regulatory Consultant Ex-FDA Independant

Bob Seevers has over 40 years of experience in the pharmaceutical research and
development. His experience includes serving as an FDA reviewer/team leader, clinical
investigator, and working in industry. After more than a decade in Nuclear Medicine, Bob spent
8 years with FDA, followed by 16 years with Eli Lilly and Company in Quality Assurance and
Regulatory Affairs. Bob has been a consultant for several years now. He has led the regulatory
CMC submission strategy for drugs in preclinical development through their NDA/BLA
submission and the approval and post-approval process for both small and large molecules.
Bob’s expertise includes regulatory strategy, writing and reviewing INDs, NDAs, and BLAs,
radiopharmaceuticals, Quality and GMPs, and Cold Chain distribution. Simply put, Bob knows
how to talk to regulators, having been one himself.
Bob has been responsible for the development of the regulatory strategy for early through latestage
regulatory filings for both large and small molecules, interaction with global regulatory
agencies, and leading cross-functional CMC development teams.
Bob has spoken at numerous national and international conferences on regulatory issues and has
served as a WHO invited lecturer on drug registration. Bob holds a bachelor’s degree of Science
in Chemistry from Lehigh University and a Ph.D. in Medicinal Chemistry from the University of
Michigan.

Seminars

Thursday 25th February 2027
Fireside Chat: How Much Preclinical Evidence Is Enough?: Defining a Fit-for-Purpose Preclinical Package to Progress RLTs Towards IND
10:00 am
  • Benchmark contrasting approaches to preclinical development to determine the level of evidence required to progress confidently towards the clinic
  • Determine which studies generate decision-critical evidence versus where additional data adds time, cost, & complexity without strengthening the development case
  • Balance toxicology, biodistribution, dosimetry, pharmacology, & model selection to build a robust package proportionate to the candidate and development stage
  • Leverage early FDA engagement to clarify expectations, ask the right scientific questions, & establish a more predictable path towards IND
Bob Seevers, Speaker at 3rd TRP Target Selection & Drug Design Summit